TMO - Outlook For 2022: Continued Investment Opportunities Related To COVID-19 Pandemic; Drug Price Legislation Flawed

• For 2022, I am going to focus on those companies poised to benefit from the tragic COVID-19 pandemic. I maintain that SARS-CoV-2 will be with us for a long time.
• As for the proposed drug price legislation in BBBA, it would impact biologics (high cost medications) only near the end of the patent life.
• Also on the BBBA proposal, it transfers significant liability for catastrophic coverage from Medicare to the plan sponsors. The result will be a dramatic increase in monthly premiums.
• I expect the next rally in the "COVID stocks" to occur after Dr. Scott Gottlieb, who is highly regarded by investors, extends his forecast for the end of the COVID-19 pandemic to well beyond his current January timetable.
• During 2021, there was "too much paper", in the form of IPOs and SPACs, for investors to absorb, and the quality of these offerings dropped dramatically as the year progressed. It has become a "stock pickers market", as many excellent companies have seen their stock decline by over 60%.

For further details see: